MX340772B - Medios y metodos para fabricar neurotoxina altamente pura. - Google Patents

Medios y metodos para fabricar neurotoxina altamente pura.

Info

Publication number
MX340772B
MX340772B MX2011008759A MX2011008759A MX340772B MX 340772 B MX340772 B MX 340772B MX 2011008759 A MX2011008759 A MX 2011008759A MX 2011008759 A MX2011008759 A MX 2011008759A MX 340772 B MX340772 B MX 340772B
Authority
MX
Mexico
Prior art keywords
unprocessed
relates
processed neurotoxin
present
methods
Prior art date
Application number
MX2011008759A
Other languages
English (en)
Other versions
MX2011008759A (es
Inventor
Pfeil Michael
Friedrich Josef
V Taylor Harold
Eisele Karl-Heinz
Brünn Cornelia
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2011008759A publication Critical patent/MX2011008759A/es
Publication of MX340772B publication Critical patent/MX340772B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo el cual enlaza específicamente a polipéptido de neurotoxina no procesado y/o parcialmente procesado o un anticuerpo el cual enlaza específicamente un epítopo el cual consiste de un péptido el cual tiene una secuencia de aminoácidos como se muestra en cualquiera de las SEQ ID NO: 1 a 16 y a métodos para la fabricación de los anticuerpos. Por otra parte, la presente invención se relaciona a una composición la cual comprende el polipéptido de neurotoxina procesado libre de polipéptido de neurotoxina no procesado o parcialmente procesado y a un método para fabricar el polipéptido de neurotoxina en base a los anticuerpos de la invención. La presente invención también se relaciona al uso del anticuerpo mencionado anteriormente para separar polipéptido de neurotoxina procesados a partir de polipéptidos de neurotoxina no procesados o parcialmente procesados o para determinar los polipéptidos de neurotoxina no procesados o parcialmente procesados. La presente invención se relaciona a un método para la fabricación de un medicamento.
MX2011008759A 2009-02-19 2010-02-17 Medios y metodos para fabricar neurotoxina altamente pura. MX340772B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20798909P 2009-02-19 2009-02-19
EP09153226 2009-02-19
US27517309P 2009-08-26 2009-08-26
EP09168679 2009-08-26
PCT/EP2010/000985 WO2010094463A1 (en) 2009-02-19 2010-02-17 Means and methods for manufacturing highly pure neurotoxin

Publications (2)

Publication Number Publication Date
MX2011008759A MX2011008759A (es) 2011-09-09
MX340772B true MX340772B (es) 2016-07-26

Family

ID=42084499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008759A MX340772B (es) 2009-02-19 2010-02-17 Medios y metodos para fabricar neurotoxina altamente pura.

Country Status (12)

Country Link
US (2) US9447175B2 (es)
EP (1) EP2398824B1 (es)
JP (1) JP5795539B2 (es)
KR (1) KR101806567B1 (es)
CN (1) CN102325792B (es)
AU (1) AU2010214834B2 (es)
BR (1) BRPI1008885B1 (es)
CA (1) CA2751311C (es)
IL (1) IL214372A0 (es)
MX (1) MX340772B (es)
RU (1) RU2571212C2 (es)
WO (1) WO2010094463A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
CA2757637C (en) * 2009-04-27 2017-10-24 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
JP5709877B2 (ja) * 2009-10-21 2015-04-30 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー プロセシングされていない及び部分的にプロセシングされたａ型ニューロトキシンを測定するためのシステム
CA2880897C (en) 2012-11-21 2020-01-14 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
EP3607977A1 (en) * 2013-01-16 2020-02-12 KCI Licensing, Inc. Ion exchange enhanced absorbent systems
WO2015188942A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE189682T1 (de) 1989-08-16 2000-02-15 Chiron Corp Prohormonspaltungsplatzblockierungsantikörper
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US6678651B2 (en) 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
WO2002036758A2 (en) * 2000-11-06 2002-05-10 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
EP1572121B1 (en) 2002-08-01 2012-01-11 The Regents of The University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US20080171347A1 (en) * 2003-04-11 2008-07-17 Atassi M Zouhair Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP2049156B1 (en) 2006-07-24 2013-09-25 The Cleveland Clinic Foundation Compositions and methods for macular degeneration
JP2008113592A (ja) * 2006-11-02 2008-05-22 Biseibutsu Kagaku Kenkyusho:Kk クロストリジウム・パーフリンゲンスの産生する新規な毒素
EP2048156A1 (en) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
MX2009012990A (es) * 2007-06-01 2010-04-01 Merz Pharma Gmbh & Co Kgaa Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.
US7732579B2 (en) * 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
WO2009014854A1 (en) 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins

Also Published As

Publication number Publication date
AU2010214834B2 (en) 2016-04-14
CA2751311C (en) 2019-08-06
KR101806567B1 (ko) 2018-01-10
US20120004179A1 (en) 2012-01-05
CA2751311A1 (en) 2010-08-26
KR20110122852A (ko) 2011-11-11
US20160340417A1 (en) 2016-11-24
AU2010214834A1 (en) 2011-08-18
BRPI1008885A2 (pt) 2016-03-15
IL214372A0 (en) 2011-09-27
JP5795539B2 (ja) 2015-10-14
BRPI1008885B1 (pt) 2021-09-28
RU2011138060A (ru) 2013-03-27
US9447175B2 (en) 2016-09-20
US9963502B2 (en) 2018-05-08
WO2010094463A1 (en) 2010-08-26
EP2398824B1 (en) 2018-12-26
RU2571212C2 (ru) 2015-12-20
MX2011008759A (es) 2011-09-09
CN102325792A (zh) 2012-01-18
EP2398824A1 (en) 2011-12-28
CN102325792B (zh) 2018-01-09
JP2012518018A (ja) 2012-08-09

Similar Documents

Publication Publication Date Title
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
EA200700136A1 (ru) Анти-cd154-антитела
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013059885A3 (en) Polypeptide constructs and uses thereof
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
WO2012046061A3 (en) Clostridium difficile antigens
WO2011063235A3 (en) Peptides, devices, and methods for the detection of ehrlichia antibodies
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
WO2012051498A3 (en) Antibodies that bind amyloid oligomers
EP2403871A4 (en) FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES
CA2837395C (en) Immunogenic composition comprising clostridium difficile toxin a and toxin b fusion protein
WO2005087811A3 (en) Estrogen receptors and methods of use
HK1201281A1 (en) Canine/feline cd20 binding epitope and compositions for binding thereto
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2011056954A8 (en) Haemophilus parasuis polypeptides and methods of use
IN2013MN00513A (es)
NZ591133A (en) Novel melanoma antigen peptide and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration